Abingdon Health has signed a new distribution agreement with Israeli company Salignostics to launch the latter’s Salistick saliva-based pregnancy test in Ireland and the UK.
Under the terms of the agreement, Abingdon Health will co-brand Salistick under its Abingdon Simply Test and sell it through its direct-to-consumer eCommerce platform as well as the company’s other pharmacy distribution channels.
The quick saliva-based pregnancy test offers users a new, improved experience and high accuracy early pregnancy detection.
It is based on Salignostics’ technology, which has been designed to detect the pregnancy hormone β-hCG in saliva.
The new test, which is CE-marked, offers the ability to perform a pregnancy test at any time as well as anywhere.
It is anticipated to receive UK regulatory approval and become available in the second quarter of the year.
Abingdon Health CEO Chris Yates said: “We are delighted to be distributing Salistick in the UK and Ireland, the first saliva pregnancy test to be launched worldwide.
“This exciting innovation offers women the opportunity to test for pregnancy in a cleaner, more straightforward and easier way, and is a long overdue development in the pregnancy testing market.
“We are excited to be partnering with Salignostics and we look forward to continuing to work with them to bring innovative self-test products to market.”
Currently, the company’s Abingdon Simply Test range includes more than 14 home-use lateral flow self-tests, which are sold direct-to-consumer through the Abingdon Simply Test website.
Abingdon Health intends to continue expanding the innovative self-test range through collaborations with innovative companies, such as Salignostics, allowing the company to bring new self-test technologies to the market.
